Indian firm Glenmark Pharmaceuticals has announced the discovery of novel chemical entity (NCE) "GRC 17536", which targets TRPA1 receptor antagonists to treat pain and respiratory disorders.
Preclinical studies of GRC 17536 have been completed, with Phase 1-enabling GLP studies in the process of completion.
GRC 17536, a highly potent TRPA1 antagonist that can be orally administered, was found to be highly efficacious in treating neuropathic pain and inflammatory pain in animal models.
The compound exhibited the positive effect of bronchoconstriction, airway inflammation and cough, and demonstrated good safety.
The company plans to file the Phase I application in January 2011.